黄斑変性症治療の世界市場レポート 2025年

黄斑変性症治療市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR11.3％で190億6,000万米ドルに成長します。予測期間の成長は、研究の進歩、ヘルスケア支出の増加、罹患率の上昇、個別化医療のアプローチ、ビジョンヘルスへの世界の取り組みに起因しています。予測期間の主な動向としては、神経保護・再生療法への注力、遠隔医療・遠隔モニタリングの拡大、個別化医療アプローチ、幹細胞療法の研究、患者中心の啓発・教育イニシアティブなどが挙げられます。

網膜障害の増加が黄斑変性症治療市場の成長を牽引すると予想されます。網膜障害は重要な組織に影響を与え、視覚情報の処理を混乱させ、歪んだ視力や障害をもたらす可能性があります。米国眼科学会（American Academy of Ophthalmology）によると、2050年までに米国では約732万人が原発性開放隅角緑内障に罹患すると予測されています。この疾患は、70～79歳（32％）、女性（50％）、ヒスパニック系（50％）に最も多く発症すると予想されています。ヒスパニック系の男性が最も多いです。その結果、網膜疾患の有病率の上昇が黄斑変性症治療市場の拡大に拍車をかけています。

高齢化人口の増加は、黄斑変性症治療市場の今後の成長を牽引すると予想されます。高齢化とは、社会や人口における高齢者の割合が高くなることを特徴とする人口動態の変化を指します。黄斑変性症治療は、高齢化社会における視力障害をターゲットとしており、網膜の中心部に影響を及ぼす状態に焦点を当てています。例えば、2022年10月に世界保健機関（WHO）は、2030年までに世界の6人に1人が60歳以上になると予測しました。この間、60歳以上の人口比率は2020年の10億人から14億人に増加すると予想されています。さらに、世界の60歳以上の人口は倍増し、2050年には21億人に達すると予想されています。したがって、高齢化人口の増加が黄斑変性症治療市場を牽引する重要な要因となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界黄斑変性症治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の黄斑変性症治療市場：成長率分析
• 世界の黄斑変性症治療市場の実績：規模と成長, 2019-2024
• 世界の黄斑変性症治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界黄斑変性症治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の黄斑変性症治療市場病気の進行度別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 初期段階のAMD
• 中等度のAMD
• 後期AMD
• 世界の黄斑変性症治療市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 外来手術センター
• 眼科クリニック
• 病院
• 世界の黄斑変性症治療市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 注射可能
• その他の投与経路
• 世界の黄斑変性症治療市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 湿性黄斑変性症
• 乾性黄斑変性
• 世界の黄斑変性症治療市場、早期AMDのタイプ別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 栄養補助食品
• ライフスタイル修正治療
• 世界の黄斑変性症治療市場、中期AMDのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗VEGF注射
• 光線力学療法
• 世界の黄斑変性症治療市場後期AMDのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 外科的治療
• 高度な抗VEGF療法
• 遺伝子治療の選択肢

第7章 地域別・国別分析

• 世界の黄斑変性症治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の黄斑変性症治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 黄斑変性症治療市場：競合情勢
• 黄斑変性症治療市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Allergan Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• GlaxoSmithKline plc
• Panoptica
• Regeneron Pharmaceuticals Inc.
• Bausch Health Companies Inc.
• Santen Pharmaceuticals
• Aerie Pharmaceuticals Inc.
• BioXcel Therapeutics Inc.
• Regenxbio Inc.
• Spark Therapeutics Inc.
• Alimera Sciences Inc.
• Applied Genetic Technologies Corp（AGTC）
• Cell Medica Ltd.
• Ophthotech Corporation
• Adverum Biotechnologies Inc.
• Neurotech Pharmaceuticals Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 黄斑変性症治療市場2029：新たな機会を提供する国
• 黄斑変性症治療市場2029：新たな機会を提供するセグメント
• 黄斑変性症治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

The macula is the central part of the retina responsible for central vision. Age-related macular degeneration (AMD) is a common condition in individuals over 60, resulting in the degeneration of the macula and causing distortion or loss of central vision. Treatment aims to slow the progression of the disease and prevent severe vision loss.

The main disease stages in the macular degeneration treatment market are early-stage AMD, intermediate AMD, and late-stage AMD. Early-stage AMD is characterized by changes in the macula with medium-sized drusen deposits and no impact on vision. Intermediate AMD may cause blurry or wavy vision due to large drusen or pigment changes. Late-stage AMD results in complete central vision loss. Macular degeneration treatments include wet and dry types, administered orally, via injection, or other methods. These treatments are utilized in various medical settings such as ambulatory surgical centers, ophthalmic clinics, and hospitals.

The macular degeneration treatment research report is one of a series of new reports from The Business Research Company that provides macular degeneration treatment statistics, including macular degeneration treatment industry global market size, regional shares, competitors with macular degeneration treatment shares, detailed macular degeneration treatment segments, market trends and opportunities, and any further data you may need to thrive in the macular degeneration treatment industry. This macular degeneration treatment research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The macular degeneration treatment market size has grown rapidly in recent years. It will grow from $11.05 billion in 2024 to $12.42 billion in 2025 at a compound annual growth rate (CAGR) of 12.4%. The growth in the historic period can be attributed to aging population, lifestyle changes, limited treatment options, rising awareness, healthcare infrastructure development.

The macular degeneration treatment market size is expected to see rapid growth in the next few years. It will grow to $19.06 billion in 2029 at a compound annual growth rate (CAGR) of 11.3%. The growth in the forecast period can be attributed to advancements in research, increased healthcare expenditure, rising incidence rates, personalized medicine approaches, global efforts for vision health. Major trends in the forecast period include focus on neuroprotection and regeneration therapies, expansion of telemedicine and remote monitoring, personalized medicine approaches, investigation of stem cell therapies, patient-focused initiatives for awareness and education.

The rise in retinal disorders is anticipated to drive the growth of the macular degeneration treatment market. Retinal disorders impact critical tissue and can disrupt the processing of visual information, resulting in distorted or impaired vision. According to the American Academy of Ophthalmology, by 2050, approximately 7.32 million people in the United States are projected to be affected by primary open-angle glaucoma, a collective term for a group of eye conditions. This condition is expected to be most prevalent among individuals aged 70 to 79 years (32%), women (50%), and Hispanics (50%). Hispanic men represent the largest demographic group affected. Consequently, the escalating prevalence of retinal disorders is fueling the expansion of the macular degeneration treatment market.

The increasing aging population is expected to drive the growth of the macular degeneration treatment market in the future. An aging population refers to a demographic shift characterized by a higher proportion of elderly individuals within a society or population. Macular degeneration treatment targets vision impairment in the aging population, focusing on a condition that affects the central part of the retina. For example, in October 2022, the World Health Organization projected that by 2030, 1 out of every 6 individuals globally would be 60 years old or older. During this period, the proportion of the population aged 60 and over is expected to rise from 1 billion in 2020 to 1.4 billion. Furthermore, the global population of individuals aged 60 and older is anticipated to double, reaching 2.1 billion by 2050. Therefore, the increasing aging population is a key factor driving the macular degeneration treatment market.

Major companies in the macular degeneration treatment market are concentrating on the development of biosimilars for age-related macular degeneration (AMD) to enhance access to effective therapies. Biosimilars are biological medical products that are highly comparable to an already approved reference product, demonstrating no clinically meaningful differences in safety, purity, or potency. For example, in May 2024, Biocon Biologics Ltd, based in India, and Samsung Bioepis Co. Ltd, a South Korean company, received FDA approval for their two new biosimilars, Yesafili and Opuviz. Both biosimilars target vascular endothelial growth factor (VEGF), which is implicated in abnormal blood vessel growth in the eye, thus helping to prevent vision loss related to AMD and diabetic retinopathy. The FDA's approval process included comparative studies demonstrating that Yesafili and Opuviz have no significant differences in efficacy or safety compared to Eylea. These studies involved comprehensive assessments of the biosimilars' pharmacokinetics and immunogenicity.

Major players in the macular degeneration treatment market are focusing on innovative solutions, such as the avacincaptad pegol intravitreal solution developed for geographic atrophy, to enhance their market performance. This solution acts as a complement C5 inhibitor targeting geographic atrophy secondary to macular degeneration. For instance, in August 2023, Astellas Pharma Inc., a Japanese pharmaceutical company, received FDA approval for IZERVAY, an avacincaptad pegol intravitreal solution designed for treating geographic atrophy (GA) linked to age-related macular degeneration (AMD). In two Phase 3 clinical trials, IZERVAY, as a complement C5 inhibitor, demonstrated a significant reduction in GA progression at the 12-month primary endpoint. Notably, the solution showed a decrease in photoreceptor loss within six months of treatment, highlighting its potential impact on addressing macular degeneration.

In July 2023, Harrow Inc., a US-based company, acquired Santen for $8 million. This acquisition is part of Harrow's strategy to enhance its portfolio by leveraging Santen's expertise in macular degeneration treatment. Santen Pharmaceutical Co., Ltd. is a Japan-based company specializing in treatments for macular degeneration.

Major companies operating in the macular degeneration treatment market include Pfizer Inc., F. Hoffmann-La Roche Ltd., Allergan Inc., Bayer AG, Novartis AG, GlaxoSmithKline plc, Panoptica, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Santen Pharmaceuticals, Aerie Pharmaceuticals Inc., BioXcel Therapeutics Inc., Regenxbio Inc., Spark Therapeutics Inc., Alimera Sciences Inc., Applied Genetic Technologies Corp (AGTC), Cell Medica Ltd., Ophthotech Corporation, Adverum Biotechnologies Inc., Neurotech Pharmaceuticals Inc., 4D Molecular Therapeutics Inc., GenSight Biologics Inc.

North America was the largest region in the macular degeneration treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the macular degeneration treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the macular degeneration treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The macular degeneration treatment market includes revenues earned by entities by anti-angiogenic drugs, photodynamic therapy, laser therapy and low vision aids. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Macular Degeneration Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on macular degeneration treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for macular degeneration treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The macular degeneration treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Stage of Disease: Early-Stage AMD; Intermediate AMD; Late-Stage AMD
• 2) By End User: Ambulatory Surgical Centers; Ophthalmic Clinics; Hospitals
• 3) By Route of Administration: Oral; Injectable; Other Route of Administration
• 4) By Types: Wet Macular Degeneration, Dry Macular Degeneration
• Subsegments:
• 1) By Early-Stage AMD: Nutritional Supplements; Lifestyle Modification Treatments
• 2) By Intermediate AMD: Anti-VEGF Injections; Photodynamic Therapy
• 3) By Late-Stage AMD: Surgical Treatments; Advanced Anti-VEGF Therapies; Gene Therapy Options
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Allergan Inc.; Bayer AG; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Macular Degeneration Treatment Market Characteristics

3. Macular Degeneration Treatment Market Trends And Strategies

4. Macular Degeneration Treatment Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Macular Degeneration Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Macular Degeneration Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Macular Degeneration Treatment Market Growth Rate Analysis
• 5.4. Global Macular Degeneration Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Macular Degeneration Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Macular Degeneration Treatment Total Addressable Market (TAM)

6. Macular Degeneration Treatment Market Segmentation

• 6.1. Global Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Early-Stage AMD
• Intermediate AMD
• Late-Stage AMD
• 6.2. Global Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ambulatory Surgical Centers
• Ophthalmic Clinics
• Hospitals
• 6.3. Global Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectable
• Other Route of Administration
• 6.4. Global Macular Degeneration Treatment Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Wet Macular Degeneration
• Dry Macular Degeneration
• 6.5. Global Macular Degeneration Treatment Market, Sub-Segmentation Of Early-Stage AMD, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nutritional Supplements
• Lifestyle Modification Treatments
• 6.6. Global Macular Degeneration Treatment Market, Sub-Segmentation Of Intermediate AMD, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anti-VEGF Injections
• Photodynamic Therapy
• 6.7. Global Macular Degeneration Treatment Market, Sub-Segmentation Of Late-Stage AMD, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Surgical Treatments
• Advanced Anti-VEGF Therapies
• Gene Therapy Options

7. Macular Degeneration Treatment Market Regional And Country Analysis

• 7.1. Global Macular Degeneration Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Macular Degeneration Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Macular Degeneration Treatment Market

• 8.1. Asia-Pacific Macular Degeneration Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Macular Degeneration Treatment Market

• 9.1. China Macular Degeneration Treatment Market Overview
• 9.2. China Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Macular Degeneration Treatment Market

• 10.1. India Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Macular Degeneration Treatment Market

• 11.1. Japan Macular Degeneration Treatment Market Overview
• 11.2. Japan Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Macular Degeneration Treatment Market

• 12.1. Australia Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Macular Degeneration Treatment Market

• 13.1. Indonesia Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Macular Degeneration Treatment Market

• 14.1. South Korea Macular Degeneration Treatment Market Overview
• 14.2. South Korea Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Macular Degeneration Treatment Market

• 15.1. Western Europe Macular Degeneration Treatment Market Overview
• 15.2. Western Europe Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Macular Degeneration Treatment Market

• 16.1. UK Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Macular Degeneration Treatment Market

• 17.1. Germany Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Macular Degeneration Treatment Market

• 18.1. France Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Macular Degeneration Treatment Market

• 19.1. Italy Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Macular Degeneration Treatment Market

• 20.1. Spain Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Macular Degeneration Treatment Market

• 21.1. Eastern Europe Macular Degeneration Treatment Market Overview
• 21.2. Eastern Europe Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Macular Degeneration Treatment Market

• 22.1. Russia Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Macular Degeneration Treatment Market

• 23.1. North America Macular Degeneration Treatment Market Overview
• 23.2. North America Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Macular Degeneration Treatment Market

• 24.1. USA Macular Degeneration Treatment Market Overview
• 24.2. USA Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Macular Degeneration Treatment Market

• 25.1. Canada Macular Degeneration Treatment Market Overview
• 25.2. Canada Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Macular Degeneration Treatment Market

• 26.1. South America Macular Degeneration Treatment Market Overview
• 26.2. South America Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Macular Degeneration Treatment Market

• 27.1. Brazil Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Macular Degeneration Treatment Market

• 28.1. Middle East Macular Degeneration Treatment Market Overview
• 28.2. Middle East Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Macular Degeneration Treatment Market

• 29.1. Africa Macular Degeneration Treatment Market Overview
• 29.2. Africa Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Macular Degeneration Treatment Market Competitive Landscape And Company Profiles

• 30.1. Macular Degeneration Treatment Market Competitive Landscape
• 30.2. Macular Degeneration Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Allergan Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Macular Degeneration Treatment Market Other Major And Innovative Companies

• 31.1. GlaxoSmithKline plc
• 31.2. Panoptica
• 31.3. Regeneron Pharmaceuticals Inc.
• 31.4. Bausch Health Companies Inc.
• 31.5. Santen Pharmaceuticals
• 31.6. Aerie Pharmaceuticals Inc.
• 31.7. BioXcel Therapeutics Inc.
• 31.8. Regenxbio Inc.
• 31.9. Spark Therapeutics Inc.
• 31.10. Alimera Sciences Inc.
• 31.11. Applied Genetic Technologies Corp (AGTC)
• 31.12. Cell Medica Ltd.
• 31.13. Ophthotech Corporation
• 31.14. Adverum Biotechnologies Inc.
• 31.15. Neurotech Pharmaceuticals Inc.

32. Global Macular Degeneration Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Macular Degeneration Treatment Market

34. Recent Developments In The Macular Degeneration Treatment Market

35. Macular Degeneration Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Macular Degeneration Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Macular Degeneration Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Macular Degeneration Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer